NEWSROOM

NASDAQ

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 13, 2024

NEW YORK, September 13, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition. Aclarion's Nociscan platform,...

AmpliTech Group’s AGTGSS Division Receives Initial Order For Its Midband 5G Radio Networks From Historic University of Edinburgh UK

AmpliTech Group’s AGTGSS Division Receives Initial Order For Its Midband 5G Radio Networks From Historic University of Edinburgh UK

Sep 12, 2024

Hauppauge, NY, September 12, 2024 – PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced receiving a purchase order for its midband 5G radio networks from Historic University of...

AmpliTech Group Announces Pricing of $1.0 Million Registered Direct Offering, Priced At-The-Market

AmpliTech Group Announces Pricing of $1.0 Million Registered Direct Offering, Priced At-The-Market

Sep 9, 2024

HAUPPAUGE, N.Y., Sept. 9, 2024 - PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW) (the “Company”), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced that it has entered into a securities purchase agreement with a single...

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Aclarion Added to PRISM Emerging Medical Devices Index

Sep 6, 2024

Company's industry-first technology addresses chronic low back pain Aclarion secured its first commercial agreement with Michigan's Sheridan Community Hospital PRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtech NEW YORK, September 06, 2024 – PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index,...

AmpliTech Group’s AGTGSS Division To Participate At Mobile World Congress Shows in Las Vegas And Barcelona To Market Its Comprehensive Private 5G End-to-End Solution for Businesses and Homes

Sep 4, 2024

This includes External and Internal CPE and Fixed 5G Wireless Access (FWA) equipment Hauppauge, NY, September 4, 2024 – PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, announces the company’s...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Sep 4, 2024

Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 - PRISM MediaWire - ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer’s and...

AmpliTech Group’s AGTGSS Division Receives Initial Order For Its Midband 5G Radio Networks From Historic University of Edinburgh UK

AmpliTech Group’s Bookings Surpass $1M In August 2024

Aug 30, 2024

In Addition To Above Bookings, Spectrum Semiconductor Materials Division Completes $700K Single Sale Transaction During The Week of August 26th 2024 Hauppauge, NY, August 30, 2024 – PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and...

BranchOut Food Delivers Shareholder Update: 2024 Revenue Surges 640% in First Half, Poised for Continued Growth and Debt Elimination by Q4 2025

BranchOut Food Delivers Shareholder Update: 2024 Revenue Surges 640% in First Half, Poised for Continued Growth and Debt Elimination by Q4 2025

Aug 28, 2024

BranchOut Food estimated to finish year at $8 million in Net Revenue Net Revenue for 1st half 2024 up over 640% from revenue in 1st half 2023 The Company estimates $5 million in Revenue for 2nd half of 2024, double that of the same period last year, to finish 2024 near $8 million Opening new production facility in Peru with about $40 mm in capacity with first production anticipated in October Completed combined financing of $5.4 million in June and July 2024 to finance completion of new...

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Aug 27, 2024

Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway Pittsburgh, PA, August 27, 2024 – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York City at the Lotte New York Palace Hotel on September 9 through 11, 2024. Admission to H.C. Wainwright’s conference is for qualified investors, and Lipella will be giving a virtual...

AmpliTech Group’s AGTGSS Division Receives Initial Order For Its Midband 5G Radio Networks From Historic University of Edinburgh UK

AmpliTech Group’s AGMDC Division Moves to Allen Tech Hub in Watters Creek District in Allen, Texas

Aug 26, 2024

Hauppauge, NY, August 26, 2024 – AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced its AmpliTech Group Microwave Design Center move into the prestigious cutting-edge Allen Tech Hub in the heart of...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

Aug 26, 2024

Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Aug 22, 2024

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)

Aug 21, 2024

New York, NY. August 21, 2024 - ANEW MEDICAL, INC. (“ANEW” or the “Company”) (NASDAQ: WENA), announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke(“TTS”)regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

Aug 21, 2024

LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer Novel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney Diseases 5th International Consultation on Interstitial Cystitis Japan runs Aug. 21-23 in Kyoto Pittsburgh, PA, August 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing...

AmpliTech Group’s AGTGSS Division Receives Initial Order For Its Midband 5G Radio Networks From Historic University of Edinburgh UK

AmpliTech Group To Hold Q2-2024 Investor’s Conference Call

Aug 20, 2024

Hauppauge, NY, August 20, 2024 – AmpliTech Group, Inc (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced the company will host an investor conference call on Wednesday, August 28th, 2024 at 5:00 PM ET. Investor Earnings...

AmpliTech Group’s AGTGSS Division Receives Initial Order For Its Midband 5G Radio Networks From Historic University of Edinburgh UK

AmpliTech Group’s AGTGSS Division Signs Memorandum Of Understanding For Initial Domestic Private 5G Network Deployment

Aug 20, 2024

With Domestic IP Data Networking, Power Storage, Cybersecurity, and IoT Company Hauppauge, NY, August 20, 2024 – AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced the signing of a Memorandum of...

SKYX to Collaborate with EGLO, European World Leading Design and Manufacturer of Decorative Lighting and Ceiling Fans

SKYX to Collaborate with EGLO, European World Leading Design and Manufacturer of Decorative Lighting and Ceiling Fans

Aug 19, 2024

The Collaboration Provides for the Joint Exploration and Product Development Potential for European and International markets for leveraging SKYX’s Technology, Product and Manufacturing Expertise of the Two Companies MIAMI, FL, August 19, 2024 - SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the "Company" or "SKYX"), a highly disruptive smart platform technology company with more than 97 issued and pending patents globally and over 60 lighting and home décor websites, announces...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Appoints New CFO

Aug 19, 2024

New York, NY, August 19, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company’s Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. “Jeff LeBlanc is a highly experienced senior executive, and we...

Sono-Tek to Present at August 20th Virtual Investor Summit Microcap Event

Sono-Tek to Present at August 20th Virtual Investor Summit Microcap Event

Aug 15, 2024

MILTON, NY, August 15, 2024 — Sono-Tek Corporation (Nasdaq: SOTK), a leading developer and manufacturer of ultrasonic coating systems, announced today that it will be presenting at the upcoming Virtual Investor Summit on August 20, 2024. Investors may request a one-on-one meeting with management by registering here: https://investorsummitgroup.com. Event: Q3 Investor SummitDate: August 20, 2024Presentation Time: 1:30 PM ETLocation: https://www.webcaster4.com/Webcast/Page/3062/51124 About...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases

Aug 15, 2024

Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW’s IP for development and commercialization in the U.S. New York, NY, August 15, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA), a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging and age-related diseases; today announced the grant and issuance of U.S. Patent No. 12,036,268 (“the 268 patent”) covering the secreted RNA splice variant of the human...

AmpliTech Group’s AGTGSS Division Receives Initial Order For Its Midband 5G Radio Networks From Historic University of Edinburgh UK

AmpliTech Group Reports Q2 Revenue of $2.5M with 1.05M Gross Profits and 42% Gross Margins

Aug 14, 2024

Hauppauge, NY, August 14, 2024 – AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced its financial results for the second quarter ended June 30, 2024. The company plans to host an investor call within...

Sono-Tek to Present at August 20th Virtual Investor Summit Microcap Event

Sono-Tek Announces Additional $2.95 Million Order from Specialty Clean Energy Customer

Aug 13, 2024

4 System Order Expected to be Shipped in Fiscal 2026 Company Experiencing Strong Demand from Clean Energy Sector MILTON, NY, August 13, 2024 — Sono-Tek Corporation (Nasdaq: SOTK), a leading developer and manufacturer of ultrasonic coating systems, is pleased to announce the receipt of an additional $2.95 million order from an existing clean energy customer. This new order, identical in value and scope to a recent record-breaking order from the same customer, reinforces Sono-Tek’s position as a...

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Aug 12, 2024

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test. Patients were tested before, during...

SKYX to Collaborate with EGLO, European World Leading Design and Manufacturer of Decorative Lighting and Ceiling Fans

SKYX Reports Record Second Quarter Sales of $21.4 Million Compared to $15.0 Million for Second Quarter 2023 as it Continues to Grow its Market Penetration in the U.S and Canada of its Advanced and Smart Platform Products

Aug 12, 2024

MIAMI, FL, August 12, 2024 – SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 97 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today reported its financial and operational results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Achievements Generated...

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Aug 12, 2024

Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” “we” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella’s Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides

Aug 9, 2024

Melanocortin receptors on neurons in the brain control feeding and weight loss Patented peptide molecules delivered orally as a pill can control feeding disorders and weight loss NEW YORK, NY, August 09, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA) has announced that, as a result of its worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona, it plans to pursue the development of therapeutics using novel proprietary peptides that selectively bind and activate...

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results

Aug 8, 2024

Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders, We are thrilled to report that we have successfully launched GraftAssureTM, which is our research-use-only assay that can detect...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS

Aug 8, 2024

Patents issued in mainland China protect the Company’s novel secreted Klotho protein and Its gene delivery system Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer’s Disease and other neurodegenerative diseases New York, NY, August 8, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the...

SKYX to Collaborate with EGLO, European World Leading Design and Manufacturer of Decorative Lighting and Ceiling Fans

SKYX Announces Corporate Update Call

Aug 7, 2024

Company to Provide Corporate Updates Including Second Quarter 2024 Financial Results; Conference Call to be Held on Monday, August 12, 2024 at 4:30 PM Eastern Time Miami, August 7, 2024 – SKYX (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive smart platform technology company with over 97 issued and pending patents in the U.S. and globally, and which owns over 60 lighting and home décor websites with a mission to make homes and buildings become smart, safe, and advanced as the...

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte Announces August Investor Conferences Participation

Aug 5, 2024

IRVINE, Calif., August 5, 2024 — Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August: 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors. Sidoti Micro-Cap Virtual Conference, August 14-15, 2024. The company is scheduled to present on Wednesday, August 14,...